Back to Agenda
Digital Health in a Post-COVID-19 Era: How the COVID-19 Pandemic Changed Regulatory Frameworks Around Telehealth and AI
Session Chair(s)
Iris Loew-Friedrich, DrMed
Executive Vice President and Chief Medical Officer
UCB SA, Belgium
Digital health, notably decentralized trials (DCTs) and artificial intelligence (AI), may improve patient engagement and help improve CT efficiency and reduce costs. The COVID-19 pandemic created both challenges and opportunities for DCTs and AI.
Learning Objective : Describe the opportunities inherent in decentralized clinical trials (DCTs) and artificial intelligence (AI) Explain the regulatory challenges presented by DCTs and AI and potential next steps Discuss lessons learned from the COVID-19 pandemic relating to DCTs and AI
Speaker(s)
Panelist
Nikolai Constantin Brun, MD
Danish Medicines Agency, Denmark
Co-Chair, EMA-MHA Big Data Task Force; Dir, Div for Medical Eval & Biostatistics
To be Announced
Jacqueline A. Corrigan-Curay, JD, MD
FDA, United States
Principal Deputy Center Director, Center for Drug Evaluation and Research (CDER)
Panelist
Patricia McGovern, MS
Novartis Pharmaceutical Corporation, United States
Global Head Innovation, Regulatory Affairs
Have an account?